Tyra Biosciences (TYRA) Depreciation & Amortization (CF) (2020 - 2026)
Tyra Biosciences (TYRA) reported Depreciation & Amortization (CF) of $138000.0 for Q1 2026, down 3.5% on a YoY basis from $143000.0 in Q1 2025, and up 4.55% quarter-over-quarter from $132000.0 in Q4 2025.
Tyra Biosciences (TYRA) Depreciation & Amortization (CF) (2020 - 2026) Analysis & Trends
Tyra Biosciences has reported Depreciation & Amortization (CF) for 7 years, with the latest figure at $138000.0 in Q1 2026.
- For the quarter ending Q1 2026, Depreciation & Amortization (CF) fell 3.5% year-over-year to $138000.0; the trailing twelve-month figure through Mar 2026 stood at $541000.0 (changed 0.19% YoY), and the FY2025 full-year result was $546000.0, up 5.2% from the prior year.
- Depreciation & Amortization (CF) for Q1 2026 stood at $138000.0, up from $132000.0 in the prior quarter.
- The five-year high for Depreciation & Amortization (CF) was $144000.0 in Q4 2024, with the low at $64000.0 in Q1 2022.
- Historically, Depreciation & Amortization (CF) has averaged $109176.5 across 5 years, with a median of $122000.0 in 2024.
- Annual changes were most pronounced in 2022 — Depreciation & Amortization (CF) surged 190.91% — and 2025, when it declined 8.33%.
- Tyra Biosciences' Depreciation & Amortization (CF) stood at $82000.0 in 2022, then grew by 24.39% to $102000.0 in 2023, then soared by 41.18% to $144000.0 in 2024, then fell by 8.33% to $132000.0 in 2025, then increased by 4.55% to $138000.0 in 2026.
- The last three Depreciation & Amortization (CF) figures came in at $138000.0 (Q1 2026), $132000.0 (Q4 2025), and $131000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | 1,395.22 |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | -1,330.00 |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 55.90 Mn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | 429,663.65 |
| 10 | Tyra Biosciences | 1.67 Bn | 1.67 Bn | - | 138,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 138,000.00 |
| Mar 31, 2026 | 138,000.00 |
| Dec 31, 2025 | 132,000.00 |
| Dec 31, 2025 | 132,000.00 |
| Sep 30, 2025 | 131,000.00 |
| Sep 30, 2025 | 131,000.00 |
| Jun 30, 2025 | 140,000.00 |
| Jun 30, 2025 | 140,000.00 |
| Mar 31, 2025 | 143,000.00 |
| Mar 31, 2025 | 143,000.00 |
| Dec 31, 2024 | 144,000.00 |
| Dec 31, 2024 | 144,000.00 |
| Sep 30, 2024 | 127,000.00 |
| Sep 30, 2024 | 127,000.00 |
| Jun 30, 2024 | 126,000.00 |
| Jun 30, 2024 | 126,000.00 |
| Mar 31, 2024 | 122,000.00 |
| Mar 31, 2024 | 122,000.00 |
| Dec 31, 2023 | 102,000.00 |
| Dec 31, 2023 | 102,000.00 |